Article citationsMore>>

Papp, K.A., et al. (2008) Efficacy and Safety of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients with Psoriasis: 52-Week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 2). Lancet, 371, 1675-1684.
http://dx.doi.org/10.1016/S0140-6736(08)60726-6

has been cited by the following article:

• TITLE: A Rare Case of Chronic Recurrent Multifocal Osteomyelitis with Undifferentiated Juvenile Idiopathic Arthritis, Uveitis, and Psoriasis

  AUTHORS: Yongdong Zhao, Shannon K. Foster, Todd J. Murdock, Margret Schlesinger, Carol A. Wallace

  KEYWORDS: Juvenile Idiopathic Arthritis, Uveitis, Psoriasis, Chronic Recurrent Multifocal Osteomyelitis, Infliximab, Ustekinumab

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.5 No.7, July 14, 2016

  ABSTRACT: We report here a 17-year-old boy with a complicated presentation of undifferentiated juvenile idiopathic arthritis, vision-threatening uveitis and chronic recurrent multifocal osteomyelitis (CRMO) in the pelvis. His severe iritis needed subtenon injections and only responded to infliximab after failing multiple biologics. Unfortunately he later developed infliximab-associated psoriasis. A combination of infliximab and ustekinumab induced remission of his arthritis, osteomyelitis, uveitis and psoriasis without experiencing severe infections.